Modelling is valuable in the planning and evaluation of interventions, especially when a controlled trial is ethically or logistically impossible. Models are often used to calculate the expected course of events in the absence of more formal assessments. They are also used to derive estimates of rare or future events from recorded intermediate points. When developing models, decisions are needed about the appropriate level of complexity to be represented and about model structure and assumptions. The degree of rigor in model development and assessment can vary greatly, and there is a danger that existing beliefs inappropriately infl uence judgments about model assumptions and results.
Introduction
Although policy decisions in public health would ideally be based on evaluations that measure eff ect directly, modelling does, and often should, play a major part in large-scale evaluations. The purpose of our Review is to assist readers to assess critically and interpret appropriately the results of such modelling exercises. We fi rst present practical and theoretical reasons why models are and should be used in large-scale evaluations. We then summarise the types of diff erent modelling approaches and discuss how models and their outputs should be judged.
The role of models in programme evaluations
Public health programmes need to be evaluated on whether anticipated benefi ts are indeed happening and whether they are cost eff ective. 1, 2 For many programmes, a randomised controlled trial is not an option for ethical or practical reasons (eg, programme implementation is done by large groups, such as national health systems, which cannot be randomised). Alternatively, the evaluation question might not be whether an intervention is eff ective, but whether it is being successfully implemented. In these cases we have to observe trends in health outcomes with the programme in place and model what would have happened without it. Even when a community-randomised trial is feasible, other activities might interfere with the eff ect of the intervention, especially if the number of communities that can be randomised is small. In such circumstances modelling is likely to play an important part in the evaluation for one of several reasons (fi gure 1). First, we might wish to estimate the causal eff ect of the programme on the health outcome of interest in circumstances in which other changes, which might aff ect that outcome, are also taking place (fi gure 1). Second, we might wish to estimate changes in a fi nal health outcome, which is diffi cult or costly to measure. In these circum stances, we might prefer to measure changes in a more easily measurable intermediate outcome and model the consequences of these changes on the fi nal endpoint of interest (fi gure 1). Third, we might wish to explore the relation between intervention and outcome to better understand fi ndings from fi eld studies. The scope of the models depends upon whether all the factors that lead to a health outcome are described and their respective roles accounted for, or whether the model is used as a quantitative framework with which to translate intermediate outcomes into a health eff ect.
In the fi rst case (attribution of eff ect), simply measuring changes in the health outcome of interest over time will not provide an estimate of the causal eff ect of the programme, because changes could have happened even in the absence of the programme. What is needed is an estimate of what would have happened in the absence of the programme (the counterfactual). This estimate can then be compared with what happened in the presence of the programme (the actual) to estimate the eff ect of the programme. Modelling can often be the only way to obtain an estimate of the counterfactual of interest.
An example is establishing the counterfactual for the trend in HIV prevalence in the context of a mature HIV epidemic. The eff ects of saturation and AIDS deaths mean that simply continuing the past trend is unlikely to show what would be seen in the absence of any intervention. For programmes that seek to change HIV risk behaviours, the recorded prevalence data can be compared with the prevalence that would be expected in the presence of saturation and population turnover but in the absence behavioural change. Such an approach was used in the recent Avahan and Global Fund evaluations, 3, 4 making the assumption that individual behaviour change can be attributed to the programme. 3, 4 In both of these exercises the uncertainty in the model parameter values and the data were used to create a counterfactual distribution, rather than a single value (fi gure 2).
There are many situations in which measuring the health outcome of interest is diffi cult or costly. Two common reasons for this are the outcome of interest is a rare event, or the outcome of interest will not happen for a long time. In both of these situations, evaluations can measure intermediate outcomes that are more frequent, or happen sooner, and then use a model to extrapolate to the outcome of interest.
A rare event, in this context, refers not only to conditions that only happen in a small number of individuals each year-eg, infection with the Ebola virus 7 or variant Creutzfeldt-Jakob disease. 8 Rather, many important public health outcomes are rare events when it comes to their measurement. For example, the primary indicators for the major health-related millennium development goals-the under-5's mortality rate and the maternal mortality ratiocannot be measured with much certainty in the most recent year in high-mortality countries because vital events are not routinely and accurately registered. Even in large sample Demographic and Health Surveys (DHS) mortality in children younger than 5 years is generally estimated for the 5 years before the survey. 9 Maternal mortality, because it is a less common event (often measured per 100 000 live-births), is even harder to measure reliably with such surveys. 10 Evaluation of a measles vaccination programme, whose goal is to reduce childhood deaths from measles, provides an example of how we can use a model to extrapolate from a more common intermediate event to a rarer, but more important, outcome. For the programme to have any eff ect, several conditions must be met. First, we need to make sure that measles vaccine is available for distribution within the country. Next, the vaccine needs to be distributed to health facilities. Then, young children need to be vaccinated at the right age (late enough to minimise interference from maternal antibodies, but early enough to protect them before they are exposed to the wild virus). This sequence of events is a causal chain that explains how measles vaccine reduces measles deaths (fi gure 3). Directly measuring changes in the number of measles deaths in children younger than 5 years is diffi cult, if not impossible, in settings where measles remains a problem. Instead of trying to measure measles deaths, we might measure the number of measles cases in children and estimate the eff ect of the measles vaccination programme on deaths due to measles with a model. 11, 12 We could further reduce data collection needs by extending the model further back up the causal chain (fi gure 3). For example, we could simply measure measles vaccine doses available in a country, or the proportion of children vaccinated, and use this information to estimate the reduction in cases of measles and deaths. A recent example of this approach estimated the eff ect of measles vaccine on child mortality, 13 as a starting point they used the number of vaccine doses given in a country. However, when intermediate outcomes are used as proxies, the further removed the intermediate outcome is from the outcome of interest the greater the uncertainty in the estimated eff ect on the modelled outcome of interest. 14 For example, a model with measles vaccine availability at country level as the intermediate outcome to estimate measles deaths averted, would produce more uncertain estimates than a model that uses the proportion of children vaccinated.
The evaluation of human papillomavirus (HPV) vaccination programmes is an illustration of a situation in which there is a long delay between the intervention and the outcome of interest. The health endpoint of primary interest is cervical cancer, which is rare and can take many years to develop. 15 To assess HPV vaccination programmes, rather than measuring the eff ect of vaccination on cervical cancer, we measure vaccine coverage and use models to predict the eff ect on infection with HPV, the precancerous lesions that will be detected in screening programmes, and the subsequent incidence of cervical cancer. Again the intermediate outcomes, HPV infections and lesions detected, could be measured to get closer to the event of primary interest (cancer rates and deaths).
Modelling is often used to aid interpretation of randomised controlled trials, especially trials of complex interventions. 16, 17 The endpoint of a trial is reached through a causal pathway that can be infl uenced by many contextual variables. To understand the recorded eff ect size and be able to generalise fi ndings to other contexts, models can be used to link trial outcomes to diff erent intermediate and process measures. 18 These measures can then be compared with values from other settings to explore the potential eff ect of the intervention. For example, the eff ectiveness of circumcision to prevent the transmission of HIV at the population level will probably depend upon the levels of sexual risk behaviour in the population. On the basis of measured effi cacy of adult-male circumcision in reducing the acquisition of the infection by circumcised men, models have been used to predict the population level eff ect of circumcision in a range of diff erent types of HIV epidemic. 19, 20 In evaluations of complex programmes with many interventions, models can be used to explore the expected contribution of diff erent elements to the overall outcome of interest. In trials, there is a trade-off between the isolation of an individual treatment being evaluated 21 and maximising the expected eff ect size by combining intervention activities and treatments. 22, 23 This trade-off often generates circumstances in which models can be used to estimate the role of the diff erent components 24 and to identify a minimum package of treatments. Model based on Hallett and colleagues. 5, 6 Vaccine doses available in country Vaccine doses distributed Children vaccinated Measles incidence Measles mortality Models can also be used to assess how an intervention should be rolled out. In the case of the randomised trials of HPV vaccine, because of the effi cacy of the vaccine, quite simple models show that vaccination is cost eff ective. 25 However, models are also needed to assess how a vaccination programme should be designed (ie, who should be vaccinated), because the possible options are too many to test in trials. 26, 27 In practice, evaluations can deal with both the attribution of eff ects in the presence of confounding factors and a lack of data on the health outcome of primary interest. In many instances, a planned assessment that involves the use of modelling is the only practical option. In such circumstances we should ask whether the modelling approach used was appropriate and whether the uncertainty inherent in the modelling process is reasonably shown in the results.
Mathematical modelling methods
Mathematics provides a precise quantitative language to describe the relation between variables and changes in states, and in medicine we can represent mathematically the clinical course of disease, the distribution of disease across populations and over time, and the mechanisms that generate disease. 28, 29 The development of a model of infection, disease, or death requires us to precisely set out our assumptions about the parameters and processes infl uencing health, and enables us to calculate the expected eff ect of programmes. Here we discuss diff erent approaches to modelling and identify a short list of key model characteristics (table) .
We draw a distinction between purely statistical models, which describe associations between variables, and mathematical models, which set out a theoretical framework that represents the causal pathways and mechanisms linking exposures, interventions, and infection or disease. Broadly, statistical models are those used to derive parameter estimates from empirical data, and mathematical models are those used to make predictions on the basis of those parameter estimates.
The development of a mathematical model involves the defi nition of equations or sets of rules that describe the 28 or numerically, with the results generated in steps for only certain sets of parameters. With numerical analysis, a range of diff erent sets of parameters are chosen to build an understanding of how the system works. 48 Mathematical models can describe the link between exposure or intervention and disease with linear or nonlinear functions. For instance, precancerous lesions can progress to cervical cancer, but can also be detected through cytological screening and excised. 49 It is reasonable to assume that the incidence of cervical cancer changes in proportion to the coverage and frequency of screening, and reducing the number of lesions by half would lead to a halving of the incidence of cervical cancer. This assumption makes prediction of the eff ect of a change simple; in fact, the linear model is so simple that it is often forgotten that it is indeed a model. Cohort models used in health economic analysis often make such linear assumptions, which assume that the fate of diff erent individuals is independent. 47, 49 Such simple functions are not widely applicable to the spread of infectious diseases, which are driven by fundamentally non-linear processes. This arises because the rate of spread of infection is determined by the rate of contact between susceptible and infected individuals, and the abundance of infected individuals is itself a function of the rate of the transmission of the pathogen. Therefore, it does not follow that halving the risk of contracting an infectious disease in a population will reduce the incidence of that disease by half. Disease incidence could change by less than half (if the epidemic has the potential to spread extensively), more than half (if the epidemic is more fragile), or be eliminated (if the epidemic is close to its threshold for persistence). 50 This complexity necessitates more involved descriptions of the relation between risk and incidence for infectious diseases.
Models can either be stochastic or deterministic. Stochastic models include chance explicitly in their results, with the diff erent possible events selected with random number generators based on the probability that they will happen. The role of chance is important when examining systems with small numbers of individuals or events, such as the spread of meticillinresistant Staphylococcus aureus in hospital wards 43 or smaller geographical regions, 29 but less so when common events in are modelled in large populations where deterministic models, which predict the average outcome, can be used. A deterministic model will produce the same results each time it is run with a given set of parameters, whereas a stochastic model will produce diff erent quantitative results each time due to the play of chance in the course of the simulation. In some cases, a stochastic model and the analogous deterministic model can produce qualitatively diff erent results, for instance when chance events trigger repeated rises and falls in the spread of the disease. 51, 52 The distinction between stochastic and deterministic models is not synonymous with the level of detail in the model, and in many cases the same model structure can be implemented with either a numerical integration algorithm (for deterministic results), or Monte Carlo simulation techniques (for stochastic results).
Another important distinction is between individualbased (microsimulation) models and population models. In the former, each individual in the population is explicitly represented and tracked. By contrast, in a population model, individuals are only represented as members of a group, with groups explicitly represented and tracked. In an individual-based model of a small population, the characteristics of each individual can be diff erent and this approach has been used to model household or institutional outbreaks of infection. 53 Often, however, many individuals are ascribed the same characteristics, but with events tracked for specifi c individuals. This approach allows large populations to be modelled as individuals more effi ciently. 27, 54, 55 Not all stochastic models are individualbased; however, all individual-based models will be stochastic. Individual-based models are powerful for two reasons. First, they allow an individual's experiences to be tracked, and second, they allow a great deal of individual level detail to be included in the analysis. However, they can be computationally intensive to use and diffi cult to interpret. Therefore population models, including important heterogeneities by stratifying the population according to diff erent criteria, are still often used.
In infectious disease, heterogeneity in the risk of acquiring and transmitting infection can allow an infection to invade a population when the same average risk in a homogeneous population would not allow this. However, this same heterogeneity that makes invasion more likely will also restrict the spread of infection. A classic example of such heterogeneity is provided by HIV, where a small fraction of a population with many contacts, such as sex workers and their clients, can acquire HIV infection while spread throughout the remaining population is limited. 56, 57 With such heterogeneity, there is the additional parameter of the form of contact between the groups, which could be completely random or not (eg, people in similar social and demographic groups might be more likely to be contacts of one another, often referred to as assortative mixing). 58 For instance, if the population of sex workers mixed randomly with everyone else, the spread of HIV could be greater than if they exclusively had sex with a small group of regular clients. 50 A homogeneous model (distinct from a model with a randomly mixing population divided into diff erent risk groups) assumes that everyone has the same risk of infection or disease, and this is often a starting point for models since it is analytically the most easily solved.
The assumptions that a model makes about how the status of individuals within a population changes over the course of infection or disease can be described in fl ow diagrams. Figure 4 shows an example of a simplifi ed fl ow diagram for hepatitis B in a homogeneous population. Alternatively it can be solved numerically, stepping through time (as shown in the fi gure for susceptibles). This simple model does not take into account age, which infl uences the probability of developing chronic infection and the probability of death. This could be included by modelling state variables with respect to age and time with partial diff erential equations. Which would be represented by equations with age specifi c parameter values such as:
Here births are at the boundary S(0,t)=births. An alternative would be to divide the state variable into specifi c age groups with diff erent diff erential equations and have individuals progress between age groups, as in realistic age structured (RAS) models. In the model for hepatitis B we might include the development of liver disease as a function of time since infection with partial diff erential equations with a risk r(a,τ') of a chronically infected person of a particular age at a particular time developing disease, these could then be summed in the integration:
to give the number developing disease at a given time. This would be called an integro-diff erential equation. The boxes describe individuals in mutually exclusive health states and the arrows describe movements into or out of these states. This can then be used to derive the model equations. The rate at which the number of individuals in each box changes (the left hand side of the model equations) is determined by the arrows, which are the terms in the right-hand side of our equations. The crucial detail of the model is the content of these terms. In our example the infection term moving individuals from susceptible to infected has an important infl uence and includes a nonlinear term representing the interaction between infectious and susceptible individuals. Our hepatitis B model (fi gure 4) is constructed to look at changes with respect to time, but it could have been constructed to look at changes over age instead (in this case it would be necessary to assume a chance of infection that is fi xed in time), or over both. Ordinary diff erential equations are used to specify the model when only tracking changes in the states over time. If it is important to track changes over other factors too, such as age (modelling progress to cancer), 60 geographical space (modelling the range of vectors), 61 or time since an event (from an infection to cancer); 62 partial diff erential equations can be used. Alternatively, discrete categories representing age groups or geographical space might be represented. Diff erential equations represent time and age as continuous variables but many models, especially in demography, represent changes in discrete steps with diff erence equations. 63 In deciding which models are appropriate to answer a particular evaluation question it should be remembered that all models are a simplifi cation of reality. Sometimes diffi cult decisions must be taken about how a system should be represented.
Assessing models
Panel 1 provides a summary checklist of items that should accompany the most rigorous model analyses. None of these indicators of model quality guarantees that the model produces accurate outputs, but the presence of this information will help readers assess the appropriateness of the model.
It is essential to have a clear understanding of the model's structure to judge model results and outputs. We believe that in addition to the full technical description of the model, there should also be a clearly presented and easily accessible lay summary, which includes fl ow diagrams of the way the disease is represented, a table showing how the model parameters were assigned, and the sources of information for the parameter values.
The specifi cation of model parameters is not simply a listing of what parameters are included (that should be evident from the fl ow diagrams or the equations), but precise defi nitions of the parameters, as well as their values and ranges. It is informative to identify where the parameter values came from, and whether or not they are based on observation, are extracted from previous modelling studies, varied depending on other parameters in the model, or estimated in the model analysis through fi tting to data.
Model validation implies that a model has been tested repeatedly across the full range of scenarios or settings to which it is supposed to apply, and has been shown to reproduce closely the independently recorded relation between input, intermediate, and outcome variables. Few, if any, models will have undergone suffi cient testing across a range of settings and situations to be deemed fully validated. At a minimum, however, presentation of a model should be accompanied by an assessment of its goodness of fi t to observed data and, ideally, how well the model predicts what was actually recorded (out-of-sample prediction). The distinction between how well a model fi ts recorded data and how well a model is able to predict what will be seen is an important one. Goodness of fi t refers to an assessment of how well the model can replicate empirical observations when the parameters in the model are adjusted to achieve the closest match. A range of methods for fi tting and assessing goodness of fi t 
Complete list of model parameters
To include clear and precise descriptions of the meaning of each parameter, together with the values or ranges for each, with justifi cation or the primary source cited, and important caveats about the use of these values noted. Where a parameter value comes from another modelling analysis, this caveat should be noted. Parameter values that are fi t in this model (not independently measured) should be clearly marked.
Assessment of model predictions with data
Illustration of agreement between model (as used in the analyses) and data or observational information. Clear statement about how model was fi tted to the data, including goodness-of-fi t measure, the numerical algorithm used, which parameter varied, constraints imposed on parameter values, and starting conditions.
Presentation of results
Key modelling results to be presented with a scientifi cally based estimate of uncertainty. Presentation of uncertainty analyses should be accompanied with statement about the sources of uncertainties quantifi ed and not quantifi ed, and these sources can include parameter, data, and model structure.
Discussion of model structure
To include the scientifi c rationale for this choice of model structure and identify points where this choice could infl uence conclusions drawn. Also to describe the strength of the scientifi c basis underlying the key model assumptions. Several diff erent parameter sets can be fi tted to the same data for urban Zimbabwe (A). The eff ect of the same circumcision intervention in women, uncircumcised men, circumcised men, and overall varies according to the set of parameter used (B). 19 are available, and the method used for this assessment should be clearly reported. When the data available to estimate the parameters are sparse and resulting estimates have wide ranges of acceptable values a model can fi t the data equally well with several diff erent sets of parameters. This problem can be benign if the model behaves the same way with diff erent parameter sets. However, in some situations, it is possible to get very diff erent predictions with diff erent, equally well fi tting, sets of parameter values (fi gure 5). This uncertainty is often hidden, but should be explicitly addressed when presenting model fi ts. One approach to quantifying this uncertainty is to identify several diff erent sets of well fi tting parameter combinations and to run the same analysis for each of these combinations. The model results can then be presented as the distribution of outputs from these analyses.
Out-of-sample prediction involves estimating model parameters with one set of data, with these parameter values within the model to make predictions and then comparing these predictions with observed data not used in the parameter estimation process. If, in a large number of instances and over a wide range of scenarios, the model predictions match the observation, this can be a powerful validation of the model (panel 2).
The presentation of sensitivity analyses and estimates of the uncertainty around modelled outputs is also important. The results of sensitivity analyses, in which parameter values are varied to establish how model outputs change, can provide important insights into the behaviour of the model. Sensitivity analyses enable readers to identify which parameter values are most infl uential in the model and which parameters should be most closely scrutinised. Sensitivity analyses, which can explore the eff ect of extreme parameter values, should be distinguished from uncertainty analyses, which seek to derive a range of credible results on the basis of an exploration of the range of reasonable parameter values. In sensitivity and uncertainty analyses, changes in a single parameter value, a limited number of parameter values or all parameter values could be explored. Parameters can be varied systematically, or chosen at random. Latin Hypercube Sampling for example, increases the effi ciency with which multiple parameter values are sampled. 48, 68 The appropriate methods for uncertainty analysis will vary according to the ambition of the exercise and constraints imposed by model complexity and computing power. The important point is that the choice of method should be presented and justifi ed.
Uncertainty analyses that explore the range of input parameters go only part of the way to the assessment of total uncertainty in the analysis, because uncertainty will also derive from the necessary decisions that were taken in the construction in the model itself. Two important elements in the assessment of the appropriateness of a model's structure are qualitative and somewhat subjective. The fi rst is construct validity: does the model's structure and its explanation accord with the biological system? Have the important causal processes been included? For example, in a model of hepatitis B does the pattern of progression, from acute infection through to chronic infection to disease, make sense? Is the contact process modelled in a way appropriate to the known spread of this virus? The second qualitative test of a model is whether a convincing explanation of the results can be provided. For example, if a model predicts that low coverage of vaccination against rubella could increase the incidence of congenital rubella syndrome, this might reasonably be explained by a delay in the average age at which girls are infected such that they are more likely to be infected when pregnant. If the model structure makes sense but the model results do not match recorded patterns of infection and disease, then either our understanding of the infection or disease is inadequate, or inappropriate parameter values have been used. Modelling can thus be used to review our understanding of an infection or disease. However, it is all too easy for the modeller to believe erroneous model results rather than challenge the validity of their model. 69 In judging construct validity, it is important to understand the scientifi c rationale for the modelling decisions taken at each stage in the analysis. There is always a trade-off in the level of detail and complexity in models. Models described as simple can be easier to interpret and explain or better scientifi cally grounded than more complex models, but the reverse can also be true. Models are designed to be a substantial simplifi cation of the real world, but we do not want oversimplifi cation that generates spurious results. In deciding on the level of detail needed it is important to consider the diff erence the detail makes to the results. Ideally we would use models with diff erent levels of detail and compare their results to identify necessary detail, but this can be a laborious process and could be best accomplished by several independent modelling groups coordinating their work. Inclusion of detail that has no relevance should be avoided: for example, in most circumstances there would be little purpose in including the sex of the child in a model of chickenpox transmission, 70 but in a model of rubella, where the outcome of interest is congenital rubella syndrome, sex is an important detail. 71 Even if a model and its application have all or most of these quality indicators, it does not guarantee that the modelled outputs are correct. The UNAIDS/WHO model of the worldwide HIV epidemic before 2004 (panel 3) had all the hallmarks of a high-quality model, but it produced results that were subsequently shown to be overestimates. Here, limited information about the biases in the estimates of HIV prevalence in pregnant women attending antenatal clinics in the surveillance system relative to the general population caused an overestimation of the scale of the epidemic. Thus, following most rigorous model analysis standards, although necessary, is not suffi cient to guarantee that the model results are accurate and using parameter estimates and modelling approaches that establish conservative estimates might be particularly appropriate to improve credibility in many situations.
Panel 2: The Life-Saved Tool
The Life-Saved Tool (LiST), 32, 64 is a model to estimate the eff ect of an increase in the coverage of a set of interventions on child mortality, and was used in the Global Fund assessments of the scale up of interventions to combat HIV, tuberculosis, and malaria. 4 Most countries covered by the assessment do not have reliable data on malaria mortality trends but they do have measures of coverage of malaria interventions such as ownership of long-lasting insecticide treated nets. LiST was used to estimate the number of malaria deaths averted by scaling up malaria interventions, including insecticide treated nets, indoor residual spraying, and treatment. This is an example of a model used to extrapolate to an outcome of primary interest. Some work that assessed how well LiST predicts changes in mortality has been done. 32, 33 In general these comparisons found that the changes in mortality predicted by LiST fell within the confi dence bounds of the measured changes in mortality. 9, [65] [66] [67] Was it appropriate to use LiST in the Global Fund assessment? Although the assessment used studies from three countries in south Asia and three countries in sub-Saharan Africa, this is a very small sample of settings and LiST cannot be deemed to have been fully validated. How well would the model perform for countries in Latin America where the levels and causes of mortality are rather diff erent from the settings used in the analyses? How well would the model perform for countries where AIDS is an important cause of child death? (In none of the settings examined was AIDS an important cause of child death.) These are questions which cannot, at present, be answered. Thus, although it might have been reasonable to use LiST in the Global Fund assessment, the model-derived predictions of deaths averted should be interpreted with caution.
Panel 3:
The UNAIDS/WHO estimates of HIV and AIDS UNAIDS and WHO developed models to estimate adult prevalence of HIV and AIDS, along with AIDS deaths, based on HIV testing of pregnant women attending for antenatal care in countries in sub-Saharan Africa. UNAIDS organised an external reference group to guide the development of the model, published descriptions of their methods and did extensive work to investigate the appropriate parameter values to use in the model. This was an on-going process, where new data were compiled and assumptions were reviewed and updated on an on-going basis. Uncertainty bounds were presented and sensitivity analyses done. In general, these estimates and the modelling on which they were based adhered to all fi ve of the indicators of model quality. However, when nationally representative data on adult HIV prevalence in countries with generalised epidemics became available from household surveys it became clear that the model overestimated HIV prevalence.
So what was wrong with the UN-led modelling on HIV prevalence and AIDS mortality? The major problems resulted from little data on which to base assumptions, especially with regard to the relation between prevalence in pregnant women in the surveillance system and all women, and the prevalence ratio between women and men. The limited data that were available had been compiled and the values for the parameters in the models were based on these data but these values were not representative of the values found in later national surveys.
UNAIDS and its partners have continued to use the same general approach to their modelling work, but now with more data available to refi ne the parameter values used in the modelling.
Discussion
With recent increases in resources committed to improve global health, there is growing demand for accountability and effi ciency in programme implementation and the need for good evaluation. In many situations, available data and appropriate modelling techniques can clarify, within a causal framework, the relation between programme inputs and eff ect. Modelling exercises that are well done can provide credible evidence of the value of programmes and guide the roll out and improvement of interventions. Unfortunately, mathematical modelling can be a confusing or daunting term and is often called and treated as a black box. We have examined the types of mathematical models that include the most common applications, although it is not exhaustive. We have attempted to provide guidance on the standards that readers should expect from a modelling paper, to promote more balanced and carefully considered view of modelling work in the hope that this enables modelling work to be more useable, more widely accepted and appropriately infl uential in this fi eld.
It is important to remember that in initial programme planning a model might be most useful when good data is not available, and yet public health policy decisions must be made-as at the beginning of an outbreak of a new respiratory pathogen. The model is valuable here for the very reason that good data is not available, and stands alone as our only method in such a setting because there is nothing else. By the time good data is available it might be too late to implement certain policies. In such a setting a good modeller will emphasise the limitations, but we cannot avoid decision making in uncertain situations.
As modelling moves from an academic exercise in mathematicians to the public health fi eld it is essential that modellers work to explain models clearly, are rigorous in quality assurance, and provide full documentation. Modellers need to be held to a high standard in terms of communication and technical skills, providing transparent analyses that can be replicated by others. To benefi t public health, non-modellers need to formulate their questions systematically, engage with modelling and hold modellers to account. Concomitantly, due consideration needs to be given to the range of choices and technical diffi culties that can be involved in modelling programmes and the time and resources needed for good quality modelling as part of evaluation, rather than modelling being an inconvenient and rushed add-on.
